Physician profile
David M Robinson
NPI 1629044284
$1,835.64
in general payments reported to CMS, 2019-2025
8 companies · $481 in 2025
The $481 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2022: $246 · 2023: $481 · 2024: $518 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $457.91 | 2022-2024 | Tezspire, Fasenra |
| Genzyme Corporation | $397.51 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $364.17 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $233.49 | 2024-2025 | Ayvakit |
| Pharming Healthcare, INC. | $125.68 | 2024 | |
| Glaxosmithkline, LLC. | $119.11 | 2025 | Nucala |
| Alk-Abello, INC | $107.04 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.